NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the potential to dramatically improve lives. The technology involved also has the potential to more efficiently get other treatments to the needed area. The company announced that tests on its signature product, ExePTEN, showed that it produced a reproducible, dose-dependent therapeutic effect in an eye model of glaucoma. This is a key finding and represents a significant step toward human testing.
